直肠癌放化疗联合或不联合奥沙利铂的近期与远期肿瘤学结局:倾向性评分匹配回顾性分析
该回顾性研究纳入伊朗癌症研究所290例局部晚期直肠癌患者,比较CAPEOX方案与卡培他滨方案放化疗的结局。倾向性评分匹配后分析29例CAPEOX与216例卡培他滨患者,多因素分析显示CAPEOX使病理完全缓解可能性增加4.38倍(CI:1.90-10.08,P<0.001),但无病生存(P=0.500)和总生存(P=0.449)无统计学显著差异。
要点
- CAPEOX组病理完全缓解可能性为对照的4.38倍(CI:1.90-10.08,P<0.001)。
- CAPEOX对无病生存无统计学显著预测价值(P=0.500)。
- CAPEOX对总生存无统计学显著预测价值(P=0.449)。
核心结论
- 加用奥沙利铂显著提高病理完全缓解率,但未转化为远期生存获益。
研究设计与样本
- 回顾性分析纳入2008年1月至2019年12月伊朗癌症研究所放疗科290例局部晚期直肠癌患者。
- 29例接受CAPEOX方案(放疗日卡培他滨625 mg/m²每日两次,每周奥沙利铂50 mg/m²)。
- 293例接受卡培他滨(825 mg/m²每日两次,少数在放疗前4天和最后1周使用5FU)。
- 采用倾向性评分匹配(无放回)后分析29例CAPEOX和216例卡培他滨患者数据。
- 使用Kaplan-Meier法和log-rank检验分析总生存和无病生存,并经倾向性评分匹配调整。
主要发现
- 倾向性评分匹配后多因素分析显示,CAPEOX使病理完全缓解可能性增加4.38倍(CI:1.90-10.08,P<0.001)。
- CAPEOX对无病生存无统计学显著预测价值(P=0.500)。
- CAPEOX对总生存无统计学显著预测价值(P=0.449)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIM: Current approaches for locally advanced rectal cancer (LARC) typically recommend neoadjuvant chemoradiotherapy (nCRT) with 5-fluorouracil (5FU) or its oral analogs followed by surgery as the standard of care. However, the question of whether intensifying concurrent chemotherapy by adding oxaliplatin to the 5FU-based backbone can yield better outcomes remains unresolved. This study aimed to investigate the benefits of incorporating oxaliplatin into fluoropyrimidine-based chemoradiotherapy (CRT) to increase locoregional control and survival. METHODS: Among 290 patients with LARC admitted to the Iran Cancer Institute's radiation oncology department between January 2008 and December 2019, 29 received CAPEOX (capecitabine 625 mg/m²/bid on RT days and weekly oxaliplatin 50 mg/m²), whereas 293 received capecitabine (825 mg/m² twice daily or rarely 5FU in the first 4 days and last week of radiotherapy (RT)). Variables potentially affecting treatment outcomes were used for propensity score matching. Kaplan‒Meier and log-rank tests were employed for overall survival (OS) and disease-free survival (DFS) analyses and were adjusted with propensity score matching. RESULTS: Data from 29 patients who received CAPEOX and 216 patients who received capecitabine were analyzed after propensity score matching without replacement. After propensity score matching, in the multivariate analysis, CAPEOX significantly increased the likelihood of achieving a pathologic complete response (pCR) by 4.38 times (CI: 1.90-10.08, p value < 0.001). However, CAPEOX did not demonstrate any statistically significant predictive value for DFS (P = 0.500) or OS (P = 0.449). CONCLUSION: The addition of oxaliplatin resulted in a significantly higher rate of pCR without any translation into long-term survival outcomes.
引用
- Azimi A, Tabatabaei FS, Kolahdouzan K, et al. Short-term and long-term oncological outcomes of chemoradiotherapy for rectal cancer patients with or without oxaliplatin: a propensity score-matched retrospective analysis. Radiat Oncol. 2024. PMID: 39627803. doi:10.1186/s13014-024-02562-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。